Atara Biotherapeutics, Inc. ATRA
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2014 · data as of November 13, 2026
Atara Biotherapeutics, Inc. (ATRA) is a healthcare company listed in the US with a market value of about $78M. In the twelve months to September 30, 2026 it had revenue of $4M and net income of -$15M, a net margin of -368.6%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -113%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 98% below the current price.
About Atara Biotherapeutics
Atara Biotherapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2014. Revenue went from $64M in 2022 to $121M in 2025, growth of about 23.9% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 212% over three years (dilution for shareholders). It spends 31% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- Interest covered more than 5 times
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $121M | $129M | $9M | $64M | — | — | — | — | — | — |
| Net income | -$15M | $33M | -$85M | -$276M | -$228M | -$340M | -$307M | -$291M | -$231M | -$119M | -$79M |
| Free cash flow | — | -$51M | -$69M | -$194M | -$275M | -$231M | -$185M | -$241M | -$216M | -$108M | -$63M |
| EPS (diluted) | $-1.12 | $2.57 | $-11.41 | $-65.19 | $-56.01 | $-90.76 | $-103.76 | $-141.77 | $-131.76 | $-100.01 | $-68.76 |
| Net margin | -368.6% | 27.1% | -66.2% | -3220.9% | -359.1% | — | — | — | — | — | — |
| ROIC | — | — | — | -139.6% | -112.2% | -87.4% | -51.2% | -76.3% | -66.9% | -68.3% | -25.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Atara Biotherapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 98% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Atara Biotherapeutics pay a dividend?
Not currently.
Is Atara Biotherapeutics a good stock to buy?
We do not give buy or sell advice. Atara Biotherapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.